News Alert: Pfizer and BioNTech begin clinical trial for Omicron-specific vaccine
  Pfizer and BioNTech have begun a clinical trial for their Omicron-specific Covid-19 vaccine candidate, they announced in a news release on Tuesday. The study will evaluate the vaccine for safety, tolerability and the level of immune response, as both a primary series and a booster dose, in up to 1,420 healthy adults ages 18 to 55.  CNN BREAKING NEWS You are receiving this newsletter because you've signed up to receive CNN Breaking News alerts.
No longer want to receive this newsletter? Unsubscribe. Interested in more? See all of our newsletters.
Create CNN Account | Listen to CNN Audio | Download the CNN App
® © 2022 Cable News Network, Inc. A WarnerMedia Company. All Rights Reserved. One CNN Center Atlanta, GA 30303
| ||||||||||||
